Global Radiopharmaceuticals Market According to Data Bridge Market Research new Market report, “By Type (Diagnostic, Therapeutic Radiopharmaceuticals), By Procedural Volumes(Diagnostic Procedures, Therapeutic Procedures), By Application(Diagnostic Application{Single-Photon Emission Computed Tomography, Positron Emission Tomography}, Therapeutic Application{Thyroid, Bone Metastasis, Lymphoma, Endocrine Tumors, Others}), By Sources (Nuclear Reactors , Cyclotrons), By End-User(Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Cancer Research Institutes, Others), By Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) – Industry Trends and Forecast is projected to reach USD 10.57 billion by 2025, at a CAGR of 9.0% during the forecast period of 2018 to 2025.
Global Radiopharmaceuticals Market According to Data Bridge Market Research new Market report– Industry Trends and Forecast is projected to reach USD 10.57 billion by 2025, at a CAGR of 9.0% during the forecast period of 2018 to 2025.
Get Your Sample Report Now! @ https://databridgemarketresearch.com/request-a-sample/?dbmr=global-radiopharmaceuticals-market-2
Global Radiopharmaceuticals Market
Radiopharmaceuticals are the drugs that can be used for either diagnostic or therapeutic purpose. This are administered to the patient and are monitored through specific imaging devices. Radiopharmaceuticals are also used in bone pain. They have preferential uptake into bone. Phosphorous 32 was the compound which was used in treating pain from bony metastases. Other radiopharmaceuticals use for this purpose are strontium-89 and samarium-153, which are commercially available in U.S. Earlier the conventional chemotherapy methods were used but now this methods have been replace by radiopharmaceuticals for cancer treatment. In diagnosis and evaluation of the prostate cancer Gallium 68 has played a very important role.
Inquiry Before Buying and Discuss Report Customization with Industry Expert @ https://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-radiopharmaceuticals-market-2
Market Segmentation:
The global market for radiopharmaceuticals by the following sub-categories is presented
By Type
Diagnostic
Therapeutic Radiopharmaceuticals
By Procedural Volume
Diagnostic Procedures
o Single-Photon Emission Computed Tomography Radiopharmaceuticals
o Positron Emission Tomography Radiopharmaceuticals
Therapeutic Procedures
o Beta Emitters
o Alpha Emitters
o Brachy Therapy
By Application
Diagnostic Application
o Single-Photon Emission Computed Tomography
Cardiology
Lymphoma
Thyroid
Neurology
Others
o Positron Emission Tomography
Oncology
Cardiology
Neurology
Others
Therapeutic Application
o Thyroid
o Bone Metastasis
o Lymphoma
o Endocrine Tumors
o Others
By Sources
Nuclear Reactors
Cyclotrons
By End User
Hospitals
Ambulatory Surgical Centers
Diagnostic Centers
Cancer Research Institutes
Others
By Geography
North America
South America
Europe
Asia-Pacific
Middle East and Africa
Speak to Analyst and Get Free Customized Information about Report @ https://databridgemarketresearch.com/speak-to-analyst/?dbmr=global-radiopharmaceuticals-market-2
FACTORS DRIVING GROWTH IN GLOBAL RADIOPHARMACEUTICALS MARKET:
Increasing incidence of cancer and cardiac ailments:
According to world health organization cancer was responsible for around 8.8million deaths in 2015. It was found that globally 1in 6 deaths is due to cancer. Low income and middle income country is responsible for around 70.0% of total deaths from cancer. 22.0% of cancer deaths is due to the use of tobacco. Hepatitis and human papilloma virus (HPV) are responsible for around 25.0% of cancer cases in low and middle income countries. Treatment was available for more than 90.0% of the high income countries. Lung cancer is responsible for 1.69 million deaths. Liver cancer is responsible for 788,000 deaths, breast cancer is responsible for 571,000 deaths.
Advances in radiotracers and alpha radio immunotherapy-based targeted cancer treatment:
Radioisotopes therapy delivers the radiation directly in to the cancer cells. Radioisotopes are usually given as a capsule, drink or by injecting into the veins. Cancer cells absorb the radioactive substance more than the normal cells hence they receive the higher dose and this leads the cell to die. Depending on what type of cancer, different types of radioisotopes are used. Iodine 131 is used in thyroid cancer and in some rare cancer. Strontium-89 and samarium-153 is used in secondary bone cancer, they helps in reducing pain. Radium-223 is used to treat secondary bone cancer, and this is the new isotope therapy.
Request For TOC@ https://databridgemarketresearch.com/toc/?dbmr=global-radiopharmaceuticals-market-2
Major Players:
Some of the major market players in the global radiopharmaceuticals market are
Cardinal Health.,
Mallinckrodt,
General Electric Company,
Lantheus Medical Imaging Inc.
Bayer AG,
Bracco Imaging S.p.A,
Nordion Inc.,
IBA,
Jubilant Pharma LLC.
Modus Medical Devices Inc,
Actinium Pharmaceuticals, Inc.,
Areva Pharma,
Merck & Co. Inc.
Navidea Biopharmaceuticals Inc.
Siemens Healthcare Private Limited,
Eckert & Ziegler,
Avid Bioservices Inc.
Alseres Pharmaceuticals Inc.
Alliance Medical Diagnostic Imaging Ltd.
Exclusive News on Global Radiopharmaceuticals Market Report @ https://databridgemarketresearch.com/news/product-launch/global-radiopharmaceuticals-market-2/
About Us:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.
Contact Us-
Data Bridge Market Research
US: +1-888-387-2818
Email:
[email protected]
Website: https://databridgemarketresearch.com